Therapeutic drug for CD55-deficient protein-losing enteropathy:pozelimab
Pozelimab is a fully human monoclonal antibody designed to block the activity of complement factor C5 and prevent diseases mediated by the complement pathway.FDA approved pozelimab,a complement inhibitor,for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy(PLE),also known as CHAPLE disease on August 18th,2023.This article reviews the mechanism of action,pharmacodynamics,pharmacokinetics,clinical efficacy and safety of pozelimab,to provide a reference for its clinical use.
NETL
NSTL
万方数据
